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Introduction: Organisms of the Burkholderia cepacia complex (BCC) are important
pathogens in cystic ﬁbrosis (CF). The majority of those who acquire BCC develop chronic
infection but it can also result in rapid decline in a signiﬁcant minority. In addition, chronic
infection with Burkholderia cenocepacia in particular is regarded as a contraindication to
lung transplantation in many units. Whilst aggressive antibiotic therapy is employed in CF
to eradicate Pseudomonas aeruginosa before infection becomes irreversibly established,
no formal assessment of such strategies has been previously reported for BCC, despite
the apparent widespread adoption of this practice. Methods: UK adult CF centers were
surveyed about their current approach to new BCC infection. Outcomes of eradication ther-
apy were assessed in patients attending the Manchester Adult CF Center with new BCC
isolates between 1st January 2002 and 1st May 2011. Patients with previous infection with
the same strain of BCC were excluded. BCC were identiﬁed at the national reference lab-
oratories and conﬁrmed by species-speciﬁc PCR and RecA sequencing. Results: Routine
use of therapies to attempt eradication of new BCC is commonly used in the UK (12/17
centers who responded).This typically involves a combination of intravenous and nebulised
antibiotics. Of 19 eligible cases of new BCC infection, the organism has been eradicated
in 7 (37%). Three of these did not receive speciﬁc eradication therapy. Of 14 patients who
have received eradication therapy and completed follow up, BCC were cleared in only 4
(29%). Conclusions:Attempted eradication of new BCC is a common practice in UK adult
CF centers. A minority of patients clear the infection spontaneously and the effects of
eradication therapies are at best modest. Early treatment may be associated with better
outcomes, though there are insufﬁcient data to support the use of any speciﬁc treatment
regimen. A prospective, systematic evaluation of treatments and outcomes is required.
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INTRODUCTION
Chronic respiratory infection is one of the hallmarks of cystic
ﬁbrosis (CF) lung disease and is the major cause of morbidity and
mortality (Gibson et al., 2003). Infection starts early in life and
tends to be persistent (Sly et al., 2009), though the nature of the
most prevalent infecting micro-organisms typically changes with
time (CF Foundation, 2009). In early childhood, chronic infection
tends to be characterized by Staphylococcus aureus but in older
subjects is dominated by gram negative organisms, particularly
Pseudomonas aeruginosa which infects around 60% of adult CF
patients in the UK (CF Trust, 2009). Other gram negative genera
including Stenotrophomonas, Ralstonia, Achromobacter, and Pan-
dorea are also increasingly cultured from CF sputum (Lipuma,
2010), and there is also growing recognition of the high preva-
lence of anaerobes (Tunney et al., 2008; Worlitzsch et al., 2009).
However, one of the most important groups of organisms causing
infection in the CF lung are the those of the Burkholderia cepacia
complex (BCC). These currently infect around 3% of UK patients
overall, and are predominantly found in adult patients, where the
prevalence is four times greater than in those under 16 years (CF
Trust, 2009).
Burkholderia cepacia complex were ﬁrst identiﬁed as important
pathogens in CF in the mid-1980s, when infection was recognized
to be associated with increased mortality and morbidity (Tablan
et al., 1985). In a minority of patients there may be a rapid and
uncontrolled deterioration with septicemia and necrotizing pneu-
monia (termed “cepacia syndrome”) that usually results in early
death (Isles et al., 1984). Patient to patient spread of organisms
occurred through social contact (LiPuma et al., 1990), particularly
for the epidemic (ET12) strain of Burkholderia cenocepacia which
was responsible for the rapid spread of the organism through some
CFunits in the early 1990s (Govan et al., 1993). This caused consid-
erable fear in the CF community and resulted in the application of
a policy of strict segregation in clinical units. The prevalence of B.
cenocepacia has fallen over the years due to the success of infection
controlmeasures preventing further spread anddue to the death of
chronically infected patients. As a result there has been consider-
able change in BCC epidemiology (Govan et al., 2007; France et al.,
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2008; Lipuma, 2010). Currently, new BCC infections are more
likely to be environmentally acquired than through contact with
other patients. Themost commonly acquiredBCC infection is now
Burkholderia multivorans (Govan et al., 2007). New infections are
usually with environmentally acquired strains (Mahenthiralingam
et al., 2005), although rarely patient to patient transmission has
also been reported (Biddick et al., 2003). In comparison with B.
cenocepacia, the clinical signiﬁcance of infection with the other
BCC species is much less clear. With important exceptions involv-
ing epidemic spread (Govan et al., 2007), B. multivorans has not
been associated with increased mortality or accelerated decline
in key outcome measures, above that associated with chronic P.
aeruginosa infection (Courtney et al., 2004; Jones et al., 2004;
Kalish et al., 2006). There are also differences between the different
BCC species post lung transplant. Patients with B. cenocepacia, but
not those infected with other Burkholderia species, have poorer
post lung transplant outcomes (Chaparro et al., 2001; De Soyza
et al., 2001), and most transplant units will not consider these
patients as candidates for lung transplantation. Concern about
B. cenocepacia however means that patients with any BCC infec-
tion are often treated similarly (CF Trust, 2004). Strict segregation
policies, designed to protect patients from acquiring and trans-
mitting BCC to other patients, contribute to the anxieties felt by
these patients and may cause additional psychological harm by
excluding them from the full range of CF unit facilities (Duff,
2002).
Clinicians have attempted eradication of newly acquired P.
aeruginosa infections for over 25 years (Littlewood et al., 1985),
and there is now good evidence that this practice is effective at
clearing initial infection and delaying the onset of chronic infec-
tion (Valerius et al., 1991; Conway and Lee, 2009). Despite the
success of this approach with P. aeruginosa and with methicillin-
resistant S. aureus (MRSA; CF Trust, 2008), eradication has not
been extended in a formal, systematicway to any other of themajor
CF pathogens, including BCC. Notwithstanding, attempted erad-
ication of newly acquired BCC infections is commonly attempted
and has been standard practice in our large tertiary adult CF cen-
ter for the last decade or so. The goals of this study were twofold:
to describe the management of newly acquired BCC infections in
adult CF centers in the UK and to examine the results of eradica-
tion strategies in our own center. The second goal involves report-
ing the new acquisitions of BCC organisms in our adult patients
over the last 9 years, the impact of transient BCC infections, and
the results of eradication strategies.
MATERIALS AND METHODS
CURRENT APPROACHES TO NEW BCC INFECTION
In order to establish how newly isolated BCC infections are cur-
rently treated in the UK, CF center directors were surveyed at
the annual UK CF Center Director meeting. Non-returns were
followed up by email.
OUTCOME OF ERADICATION THERAPY
Patients attending the Manchester Adult CF Center, a large
tertiary-referral adultCF center (370patients) in theNorthWest of
England, were included if they had new respiratory isolates of any
BCC species between 1st January 2002 and 1st May 2011. Patients
with infection caused by other species of Burkholderia, or with
their ﬁrst isolate of the same BCC organism before this date, and
those whose ﬁrst episode of infection with the same BCC was prior
to transferring their care to our center were not included. Date of
acquisition was deﬁned as the date the organism was ﬁrst cul-
tured on selective medium from sputum samples. BCC infection
was classiﬁed as having been eradicated if at least three consecu-
tive cultures failed to yield the organism over a minimum period
of 12months, as per current UK CF Trust recommendations (CF
Trust, 2004).
Historical annual rates of BCC infection and acquisition were
calculated from records of the numbers of infections that occurred
in a calendar year,with the total numbers of patients taken as those
attending the unit at the end of that year. Incidence was expressed
as the number of cases per 100 patients. Data include those from
a previously published series (France et al., 2008).
Throughout this period, BCC-selective media were routinely
used in the microbiology laboratory for analysis of all CF sputum
samples. Organisms detected on selective media were formally
identiﬁed as BCC at the national reference laboratories and con-
ﬁrmed by species-speciﬁc PCR and RecA sequencing. Genotyping
by pulsed ﬁeld gel electrophoresis (PFGE) was performed on all
isolates and repeated when the interval between repeat positive
samples was greater than 12months.
There was no formal eradication protocol during the study
period,but patientswithnewBCC infectionswere typically offered
admission for intravenous (IV) antibiotics, followed by nebulised
tobramycin with or without additional oral antibiotics. The exact
choice, in the absence of evidence based guidelines or a formal pro-
tocol, was determined by organism sensitivities, patient allergies
and preference, and logistics.
RESULTS
CURRENT APPROACHES TO NEW BCC INFECTION
Responses were obtained from 36 CF units (75% of all UK spe-
cialist CF centers), representing over 6300 patients and including
19 pediatric and 17 adult centers. Because of the rarity of new
BCC infection in pediatric centers, many of these reported little
or no recent experience of the issue. For this reason, only replies
from the 17 adult centers (representing 3560 patients) have been
analyzed further.
Twelve adult CF centers, representing 2860 patients, always
attempt eradication of newly isolated BCC. Two additional centers
attempt eradication only in the presence of additional indications.
Only twounits had a formal eradicationpolicy. Intravenous antibi-
otics were used in all cases, for a median of 2 (range 2–6) weeks,
typically comprising combined IV tobramycin and meropenem
with additional therapy consisting of co-trimoxazole (n= 4),
ceftazidime (n= 5), and chloramphenicol (n= 2).
Nebulised antibiotics (typically tobramycin or meropenem)
were also used in 13 of these 14 centers, for a median of 12 weeks
(range 8 weeks – indeﬁnite). Five centers used additional oral
antibiotics, for a median of 7 (2–12) weeks. This most commonly
involved minocycline (n= 4) and/or co-trimoxazole (n= 5).
Of the 12 centers that always attempted eradication, 8 (67%)
estimated success rate of eradication therapy to be less than
50% (Figure 1). In the ﬁve centers where eradication was not
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routine, factors that dissuaded clinicians were perceived poor suc-
cess of treatment (n= 5), toxicity (n= 3), cost (n= 1), and lack of
experience with this approach (n= 2).
EPIDEMIOLOGY OF NEW BCC INFECTIONS
The changing epidemiology of BCC infections at the Manchester
Adult Center over the last 30 years are presented in Figure 2. Rates
of B. cenocepacia infection have dropped sharply since partial, and
then full, segregation of patients was introduced in 1991 and 1994
respectively (France et al., 2008). Rates of B. multivorans acquisi-
tion on the other hand have remained static at an average of 1 new
case per 200 patients over the last 10 years.
Between 1 January 2002 and 1st June 2011 there were 22 new
BCC isolates: 16 (73%) B. multivorans, 4 B. cenocepacia (17%)
and 1 each of B. latens, and B. vietnamiensis. A single new iso-
late of B. gladioli was excluded from further analysis. One of the
B. cenocepacia infections was due to the epidemic ET12 strain,
acquired through patient to patient contact after the patient chose
to ignore explicit infection control advice. All of the remaining
FIGURE 1 | Estimated success of BCC eradication therapy in UK adult
CF centers. In all but one of these centers, the practice was routinely
applied to all new BCC infections.
FIGURE 2 | Relative incidence of newly acquired B. multivorans and
B. cenocepacia infections in CF patients attending the Manchester
Adult CF Center. Incidence is expressed as number of cases in a calendar
year per 100 patients. Total number of patients refers to that attending the
clinic at the end of the year.
infections were due to individual sporadic strains, with the possi-
ble exception of the single infection with B. latens. This was one
of a localized cluster of three patients with B. latens, in whom it
is not clear whether cross-infection has occurred or whether the
patients have been infected from a common environmental source
(Horsley et al., 2011).
Mean age of acquisition was 29 years (range 18–51 years; see
Table 1). Data on baseline clinical variables and eradication ther-
apy are missing in one case. In the remaining 21 patients, mean
forced expiratory volume in 1 s (FEV1) was 56% predicted (27–
94%) and mean body mass index (BMI) was 21.1 (17.0–25.8) at
time of ﬁrst isolate. Seventeen patients (81%) were chronically
infected with P. aeruginosa. 10 patients were also infected with S.
aureus (48%), and 14 (67%) with one or more of Aspergillus sp.,
Candida sp., or other yeasts.
ERADICATION
In two cases it is still too early to report on eradication outcomes.
In one further case, B. cenocepacia was identiﬁed on a single iso-
late only after the patient had died. These cases are highlighted in
Table 1, and excluded from further analysis.
Of the remaining 19 cases, eradication has been achieved in
7 (37%); comprising 5 cases of B. multivorans and 1 each of B.
vietnamiensis and B. cenocepacia (see Table 1). However, four of
these seven were only single isolates (three of B. multivorans and
one of B. vietnamiensis), three of which did not receive any speciﬁc
therapy.
Although antibiotics for BCC eradication were prescribed in
14 completed cases, and included combinations of 2–5 antibiotics
for a median of 28 days (maximum 84 days), only four of these
patients (29%) successfully cleared the infection. There was no
signiﬁcant association between receiving eradication therapy and
successful eradication of BCC infection (p= 0.25, Fisher’s exact
test), see Table 2. In one case (#11), it is unclear whether eradica-
tion therapy was prescribed, and this has been excluded from the
analysis in Table 2.
Overall, 4 of 14 treated patients and 3 of 4 untreated patients
eradicated BCC. However, these three untreated cases were all sin-
gle isolates, in whom subsequent negative cultures were already
available.
There was no consistent eradication regimen applied during
the period of study, see Table 1. Antibiotic regimens consequently
reﬂect individual microbiological sensitivities, patient allergies,
and preferences. It has therefore not been possible to identify
any aspects of treatment regimens, either the antibiotics used,
the length of treatment or route of delivery, that impact on
outcomes. Overall, 10 patients received IV antibiotics as either
part or whole of their eradication therapy. Intravenous regimens
contained meropenem in 8/10 cases, tobramycin in 6 and co-
trimoxazole in 4 cases. In eight cases, oral antibiotics were used
to supplement or to extend IV therapy, and in six cases were
used without prior IV antibiotics. Oral regimens contained co-
trimoxazole in 10/14 cases,minocycline in 8, doxycycline in 2, and
ciproﬂoxacin in 5.
The four patients in whom eradication was successful received:
(i) 28 days of oral co-trimoxazole, ciproﬂoxacin, and minocycline,
(ii) 28 days of oral co-trimoxazole and minocycline combined
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Table 1 | Demographics, treatment, and outcomes of patients with new BCC infections.
Patient
number
Burkholderia
species
Other chronic
respiratory
infections
Age
(years)
FEV1%
predicted
BMI Eradication
regimen
Outcome number+ve
isolates [time in days
between 1st and last]
1 multivorans SA, yeast 20 54.9 23.7 14 day M, Co,T then 28 day S, T(N) Chronic
2 multivorans PA, Asp, C, Sten, Pan,
MRSA
27 72.4 18.8 14 day M,T, Ch, D Chronic
3 cenocepacia PA, C 30 36.5 25.6 14 day M,T, Cz, Co Chronic
4 multivorans PA, Asp 23 75.4 22.4 21 day Mi, Co then 14 day M,Te Chronic
5 multivorans PA, SA, Asp 31 94 25.1 28 day Co, Cf Chronic
6 multivorans SA 21 61.6 20.7 28 day Co, R, T(N) Chronic
7 multivorans PA, SA, Asp 19 82.1 22.1 28 day Cz,T, Co, Cf, M(N) Chronic
8 multivorans PA, Asp 35 27.1 17 28 day M andT(N) Chronic
9 multivorans PA, SA, Asp, AX 20 73.3 20 28 day Mi, Co, T(N) Chronic
10 multivorans PA, C 51 49.2 18.1 7weeks Cf, Mi Chronic
11 cenocepacia ? 24 ? ? ? Chronic
12 latens PA, SA, Asp, C 25 39.8 18.8 None Chronic
13 multivorans PA, Asp, yeasts 42 39.2 22.7 12weeks Mi, Co, 14 dayAz,Ta, M Eradicated 5 [56]
14 cenocepacia PA, SA, C, Trich 24 55.1 21.8 14 dayTe,Ta, Co, Mi Eradicated 3 [19]
15 multivorans PA, Asp 18 32 17.7 28 day Mi, Co, Cf Eradicated 1
16 multivorans PA 38 45.3 19.8 28 day Mi, Co, T(N) Eradicated 5 [44]
17 multivorans PA, HI 21 36.9 21.9 None Eradicated 1
18 multivorans PA 31 87.4 25.8 None Eradicated 1
19 vietnamiensis PA, SA, C, Serratia 27 83.7 21.1 None Eradicated 1
20 cenocepacia Asp, Ewingella, yeasts 36 25.2 18.8 Isolated whilst on treatment See notes1
21 multivorans PA, SA 22 62.1 22.9 14 day M, Co,T then 6weeks Mi,
Co, Cf
Too early
22 multivorans MRSA, Asp 42 35.5 19.1 21 dayTa, M,T then 6weeks Co, D Too early
BMI, body mass index; SA, Staphylococcus aureus; PA, Pseudomonas aeruginosa; Asp, Aspergillus fumigatus; C, Candida sp.; Sten, Stenotrophomonas maltophilia;
Pan, Pandorea sp.; MRSA, methicillin-resistant Staphylococcus aureus; AX, Achromobacter xylosoxidans; Trich, Trichosporon beigelli; HI, Haemophilus inﬂuenzae;
Serratia, Serratia marascens; Ewingella, Ewingella americana.
Az, aztreonam; Cf, ciproﬂoxacin; Ch, chloramphenicol; Co, co-trimoxazole; Cz, ceftazidime; D, doxycycline;M,meropenem;Mi,minocycline; R, rifampicin;T, tobramycin;
Ta, tazocin; Te, temocillin; (N), nebulised; d, days; wks, weeks. ?, data missing.
Intravenous therapies highlighted in bold.
For those patients in whom BCC were eradicated, the number of BCC positive sputum cultures, and the time interval between the ﬁrst and last of these, are given
in the ﬁnal column. All patients with chronic infection have had multiple positive cultures.
Cases 19–22 (shaded in gray) have incomplete data and have been excluded from subsequent analysis.
1Burkholderia cenocepacia identiﬁed only after patient death.
Table 2 | Summary of numbers of patients treated and treatment
outcomes.
BCC eradicated Chronic infection Total
No treatment 3 1 4
Eradication therapy 4 10 14
Total 7 11 18
The total of 18 patients does not include one case where the records are unclear
as to what treatment the patient received (#11 inTable 1).
with nebulised tobramycin, (iii) 14 days of intravenous temocillin,
tazocin, and co-trimoxazole combined with oral minocycline, and
(iv) 14 days of intravenous aztreonam and tazocin followed by
14 days of intravenous meropenem combined with 12weeks of
oral minocycline and co-trimoxazole. In all four cases where erad-
ication was successful, the BCC appear to have cleared quickly.
One case was a single isolate of B. multivorans, one was B. ceno-
cepacia present on three occasions a maximum of 19 days apart,
one was B. multivorans present on ﬁve occasions a maximum of
44 days apart, and the ﬁnal case was B. multivorans present on
four occasions a maximum of 56 days apart. In the ﬁrst three of
these cases, the organism was not isolated again after eradication
therapy was started. In the ﬁnal case, no further BCC were isolated
once intravenous therapies were started, after an initial failure of
oral co-trimoxazole and minocycline alone.
After discussions, a single patient elected not to receive spe-
ciﬁc eradication therapy, and developed chronic infection with B.
latens.
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CHRONIC INFECTION
Of the 13 chronically infected patients, 3 subjects have had inter-
vals of over 1 year between positive isolates, all conﬁrmed by geno-
typing as being due to the same organism. The maximum time
interval between isolates was 29months, with 26 negative spu-
tum cultures. Genotyping by PFGE analysis conﬁrmed that these
two were the same strain of B. multivorans, representing either
re-infection from the same environmental reservoir or persistent
undetected infection.
CONCLUSION
This study highlights a number of important features of current
practice with regards to BCC infection in CF, and is the ﬁrst to
report data on attempted eradication of new infections. We have
shown that whilst this practice is widespread in the UK, it is poorly
standardized and may be of little value in the majority of cases.
Data from our own unit have shown that spontaneous clearance
of new BCC infection occurs in at least 17% of cases, though the
true value may be higher. It is not possible to know whether the
cases apparently responding to eradication therapy would have
cleared the infection without additional assistance, nor whether
there are more cases of transient infection in CF that are acquired
and cleared between sputum sampling at clinic.
The success of patient segregation is borne out by the low rates
of new B. cenocepacia infection. This has resulted in a shift in
BCC epidemiology compared to an earlier published series from
the same CF clinic (Jones et al., 2004). In the period covered by
the earlier paper (1982–2003), 33/57 (58%) of newly acquired
BCC infections were due to B. cenocepacia, the majority of these
caused by the epidemic ET12 strain, and 16 (28%) were caused
by B. multivorans. Of the 18 new BCC infections in the unit since
this earlier study, 14 (78%) have been due to B. multivorans, and
only two have been due to a sporadic strain of B. cenocepacia (see
Figure 2). This changing epidemiology is already well described
(Govan et al., 2007; France et al., 2008) and the falling rates of new
B. cenocepacia infection reﬂect the effects of routine surveillance
for BCC (using speciﬁc culture media) combined with strict seg-
regation policies. By contrast, rates of new sporadic BCC infection
have remained relatively stable over this period (France et al., 2008;
see Figure 2). These are probably acquired from as yet unknown
environmental reservoirs, and the prevalence is likely to increase
as the CF population gets older.
Little data exist on outcomes except for the two most common
BCC infections and whilst it appears that B. multivorans in the
majority of cases is not as virulent a pathogen asB. cenocepacia, the
infection is not without consequence. Three studies have reported
no greater decline in lung function or BMI with chronic B. multi-
vorans, compared to that seen with chronic P. aeruginosa infection
(Courtney et al., 2004; Jones et al., 2004; Kalish et al., 2006). In
the two studies where it was reported, there was no apparent
impact on survival of acquiring chronic infection with B. multivo-
rans (Jones et al., 2004; Kalish et al., 2006). However, the numbers
involved in both studies were relatively small (covering a total of 41
patients with B. multivorans infection), and the follow up period
of the larger study was far too short to make deﬁnitive observa-
tions about survival (Kalish et al., 2006). These comparisons have
only been performed against patients with chronic infection with
P. aeruginosa, an organism already known to be responsible for
a more rapid deterioration in health (Emerson et al., 2002), and
not against those with no chronic infection. Only with a longer
study, on greater numbers of patients, would we be conﬁdent that
B. multivorans infection had no additional impact on survival. It
is unlikely to be entirely benign however. In vitro, B. multivorans
has been shown to induce an inﬂammatory response similar to
that of B. cenocepacia (Kaza et al., 2011). Patients with chronic B.
multivorans infection can suffer accelerated decline and the classi-
cal features of cepacia syndrome have been described (Zahariadis
et al., 2003; Jones et al., 2004). Occasional strains of B. multivorans
have also been associated with epidemic spread, though unlike
with B. cenocepacia the mode of transmission has not been iden-
tiﬁed (Baldwin et al., 2008). In addition to the open question of
the clinical signiﬁcance, infection with BCC has important con-
sequences for the patient. Segregation may involve reduced access
to specialist facilities and this, combined with the anxiety of being
infected with a member of the feared “cepacia” family of organ-
isms, can contribute to the psychological impact of infection with
these pathogens (Duff, 2002).
If it is accepted that infection with even the sporadic strains of
BCC is a signiﬁcant event, then the issue of how this is managed
becomes relevant. There are no national or international guide-
lines that the authors are aware of, and no reports of how new
BCC is approached in other countries. Despite both the lack of any
prior evidence of efﬁcacy and the requirement for expensive and
potentially toxic therapies, attempted eradication of new BCC is
commonly attempted in adult CF centers in the UK.What is more,
even in those centers where eradication is routinely attempted,
there is a broad pessimism about the outcomes, with two-thirds
of centers recognizing the below-50% success rate that we have
reported here.
Our own attempts to institute eradication therapy have been
only partially successful. Not all patients have received treatment,
and the approach has varied both with time and with microbio-
logical and patient factors. The current practice is to offer an initial
2-week course of intravenous antibiotics containing three differ-
ent agents, one of which is usually co-trimoxazole (which may be
givenorally if the patient is undergoinghome therapy). This is then
followed with 6weeks of two to three oral antibiotics, again usu-
ally containing co-trimoxazole, combined with either nebulised
tobramycin or meropenem. No conclusions can be drawn from
the results presented here about the optimal nature of the eradica-
tion regimen,and the evidence for this treatment schedule is drawn
froma combination of in vitro studies, case reports, and an attempt
to minimize the potential adverse effects of treatment. Aaron et al.
(2000) reported on the individual and combined antibiotic sus-
ceptibility of BCC to 10–15 different antibiotics. They did not
differentiate by species, but since these were clinical isolates from
the 1990s, they are likely to have been predominantly B. ceno-
cepacia. They found a poor response to single agent treatments
but much greater efﬁcacy of combined therapy. The most effec-
tive combinations were those including meropenem, tobramycin
and ceftazidime (effective against 93% isolates), septrin (88%),
chloramphenicol (87%), or aztreonam (87%). A number of clin-
ical reports have conﬁrmed the efﬁcacy of IV meropenem against
BCC during exacerbation (Ciofu et al., 1996; Kuti et al., 2004;
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Weidmann et al., 2008), though eradication has not been an aim
or a feature of these reports. In CF patients who had undergone
lung transplantation, an aggressive approach to post transplant
eradication of BCC was adopted by the Toronto lung transplant
clinic. They treated patients with IV ceftazidime, chlorampheni-
col, tobramycin, septrin and nebulised tobramycin for 3months
post transplantation (Chaparro et al., 2001). In three out ﬁve cases
of multi-resistant BCC, the regimen appears to have been suc-
cessful in preventing re-infection post transplant. The other 20
patients who did not receive this regimen were all BCC positive
after transplantation.
Nebulised tobramycin has been used with some success in 2
case reports of successful treatment of cepacia syndrome (Weid-
mann et al., 2008; Grimwood et al., 2009). Nebulised tobramycin
in combination with nebulised amiloride has also been used as
an eradication therapy in two case series. In the ﬁrst, it was used
to treat four adult CF patients with early growth of BCC, and
appeared to be successful in three out of four cases (one B. ceno-
cepacia; one B. ambifaria, one unclear; Middleton et al., 2005).
However, a later report of outcomes in seven children reported
successful eradication in only one patient (B. stabilis), when given
twice daily in patients who had infection for up to 10 years (Ball
et al., 2010). The numbers involved mean it is not possible to
draw ﬁrm conclusions, but the difference in outcomes may relate
to the chronicity of the infection. In those cases where eradica-
tion was successful, the infection had only been present for a
short period of time. A similar observation can be made with
the data presented here. In the four patients in whom eradication
was successful, treatment was started within 2 months of the ﬁrst
isolate, and in three cases no further positive sputum cultures were
found after the start of treatment. Early lack of response to erad-
ication therapy may be an indication to change or abandon the
approach.
The impact of eradication therapy in newly acquired BCC
infection however has been disappointing. It is also possible that
inadequate antibiotic treatment may cause more harm than good
by inducing potentially harmful phenotypic change in the infect-
ing organism (Zlosnik et al., 2010). In the current series, only
4 of 14 patients who received eradication therapy went on to
clear the infection, though we cannot know whether these patients
would have cleared the infection anyway. For even without speciﬁc
therapy, infections may be cleared in a signiﬁcant minority. Quite
why this occurs is less clear. There is a highly diverse clinical course
following acquisitionof BCC infection,and spontaneous clearance
may represent one end of a spectrum delineated by cepacia syn-
drome at the other. Phenotypic variation exists within individual
BCC species, and exopolysaccharide production has been associ-
ated with clinical outcome (Zlosnik et al., 2010). Much remains
unknown however about the interaction between BCC and the CF
lung, and the inﬂuence of other host and bacterial virulence fac-
tors have yet to be deﬁned. In addition, virulence may also change
over time due to genetic recombination. There is already evidence
of signiﬁcant transfer of genetic information from epidemic B.
cenocepacia to B. multivorans, a process that is believed to have
occurred in the clinical environment (Baldwin et al., 2008).
A ﬁnal important observation is that the interval between pos-
itive isolates can be prolonged. This emphasizes the need for
continued surveillance and segregation. The current UK recom-
mendation of at least 12months of negative cultures before a
patient is considered to have cleared the infection (CF Trust, 2004)
may not be adequate for some patients.
It is important to recognize that there are signiﬁcant limita-
tions to the data presented here. The data are from a single center,
involving a small number of subjects over a prolonged period
during which the approach to new BCC infections has not been
uniform. These results highlight the need for a thorough study of
this question.
In conclusion, we are really no closer to answering the ques-
tion of whether early BCC infection in CF can be eradicated with
antibiotic therapy. We have shown that the practice of giving ther-
apy to eradicate newly acquired BCC infections is widespread in
adult CF units in the UK and have presented data, based on our
own experience, that eradication is unsuccessful in the majority of
cases. This is borne out by the estimates of success rate in other
units. We have also shown that spontaneous clearance of infection
occurs without treatment, which may be responsible for some
of the apparent successes of eradication therapy. Looking to the
future, and recognizing the potential clinical and psychological
impact of untreated BCC infection, it is important that a rigorous
and systematic evaluation be undertaken of the practice of erad-
ication in order to avoid the inappropriate use of expensive and
potentially harmful therapies.
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